Rivers T, Schwentker F. 1935. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. J Exp Med, 61:689–702. Salama H, Hong J, Zang Y, et al. 2003. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. Brain, 126:2638–47. Sormani M, Rovaris M, Valsasina P, et al. 2004. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology, 62:1432–4. Teitelbaum D, Brenner T, Abramsky O, et al. 2003. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efﬁcacy. Mult Scler, 9:592–9. Teitelbaum D, Fridkis-Hareli M, Arnon R, et al. 1996. Copolymer 1 inhibits chronic relapsing experimental aller/gic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP- speciﬁc T cell responses. J Neuroimmunol, 64:209–17. Teitelbaum D, Milo R, Arnon R, et al. 1992. Synthetic copolymer 1 inhibits human T-cell lines speciﬁc for myelin basic protein. Proc Nat Acad Sci USA, 89:137–41. Glatiramer acetate Tselis A, Khan O. 2004. Multiple sclerosis. A case for early treatment. In Olek M (ed). Multiple sclerosis. biology, diagnosis and new treatment strategies. Totowa, NJ: Human Press. p 131–43. Vieira P, Heystek H, Wormmeester J, et al. 2003. Glatiramer acetate pro- motes Th2 cell development and increased IL-10 productiion through modulation of dendritic cells. J Immunol, 170:4483–8. Weber M, Starck M, Wagenpfeil S, et al. 2004. Multiple sclerosis: glat- iramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain, 127:1370–8. Wolinsky J. 2004. The PROMiSe trial: baseline data review and progress report. Mult Scler, 10:S65–S72. Wolinsky J, Comi G, Filippi M, et al. 2002. Copaxone’s effect on MRI- monitored disease in relapsing MS is reproducible and sustained. Neurology, 59:1284–6. Ziemssen T, Kumpfel T, Klinkert W, et al. 2002. Glatiramer acetate- speciﬁc T-helper-1 and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain, 125:2381–91. Neuropsychiatric Disease and Treatment 2007:3(2) 267